ViewRay Climbing A Steep Hill As It Tries To Disrupt The Radiation Oncology Market

Small-cap rad-onc company ViewRay (VRAY) certainly doesn't lack for ambition, as it is trying to disrupt the $5 billion radiation oncology equipment market with its MRI-guided MRIdian system. While ViewRay brings a lot of positives to the table that should presage meaningful market growth, the reality is that treatment approaches often change much more slowly than investors would otherwise expect and it's not clear to me that cancer centers will see the same advantages in ViewRay's approach.

While I believe ViewRay has a better chance of disrupting the market than Accuray (ARAY) (which I own), there are lots of lessons from the Accuray experience that apply here - particularly radiation oncologists' satisfaction with the status quo and their lack of perceived need to change. Still, with the shares already pricing in very little chance of long-term success, this name could hold interest for more speculatively-minded investors, particularly after a recent capital raise that brought in some interesting strategic investors.

To read the full article, click here:
ViewRay Climbing A Steep Hill As It Tries To Disrupt The Radiation Oncology Market